Evidence map›Paper›PMID 29436688›Full record

ArticleInternational journal of molecular medicine2018

Necrostatin-1 protects C2C12 myotubes from CoCl2-induced hypoxia.

Rui Chen, Jiehua Xu, Yanling She, Ting Jiang, Shanyao Zhou, Huacai Shi, Cheng Li

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Curcumin Protected CoClFood science & nutrition · 2026
    Article
  5. The molecular mechanisms and therapeutic implications of PANoptosis in ischemic diseases.Apoptosis : an international journal on programmed cell death · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Necrostatin-1: a promising compound for neurological disorders.Frontiers in cellular neuroscience · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rui ChenGuangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317, P.R. China.
Jiehua XuDepartment of Nuclear Medicine, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China.
Yanling SheGuangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317, P.R. China.
Ting JiangDepartment of Radiology, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China.
Shanyao ZhouGuangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317, P.R. China.
Huacai ShiGuangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317, P.R. China.
Cheng LiGuangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317, P.R. China.
Guangdong Work Injury Rehabilitation Hospital · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Necrostatin-1 (Nec-1) is a selective and potent allosteric inhibitor of necroptosis by specifically inhibiting the activity of receptor‑interacting protein (RIP) 1 kinase. The aim of the present study was to determine the effect of Nec‑1 on an anoxia model comprising mouse skeletal C2C12 myotubes. In the present study, a hypoxic mimetic reagent, cobalt chloride (CoCl2), was used to induce hypoxia in C2C12 myotubes. The cytotoxic effects of CoCl2‑induced hypoxia were determined by a Cell Counting kit‑8 assay and flow cytometry. Transmission electron microscopy (TEM) was used to characterize the morphological characteristics of dead cells at the ultrastructural level. To clarify the signaling pathways in CoCl2‑mediated cell death, the expression levels of RIP1, RIP3, extracellular signal‑regulated kinase (ERK)1/2, hypoxia‑inducible factor (HIF)‑1α and B cell lymphoma‑2 adenovirus E1B 19‑kDa interacting protein 3 (BNIP3) were investigated by western blotting. Oxidative stress was determined using 2',7'‑dichlorofluorescin diacetate to measure intracellular reactive oxygen species (ROS) and the fluorescent dye JC‑1 was used to measure mitochondrial membrane potential (Δψm). The results showed that the ratios of apoptotic and necrotic C2C12 cells were increased following CoCl2 treatment, typical necroptotic morphological characteristics were able to observe by TEM, whereas Nec‑1 exhibited a protective effect against CoCl2‑induced oxidative stress. Treatment with Nec‑1 significantly decreased the levels of RIP1, p‑ERK1/2, HIF‑1α, BNIP3 and ROS induced by CoCl2, and promoted C2C12 differentiation. Nec‑1 reversed the CoCl2‑induced decrease in mitochondrial membrane potential. Together, these findings suggested that Nec‑1 protected C2C12 myotubes under conditions of CoCl2-induced hypoxia.

Indexed as

AnimalsApoptosisCell DeathCell HypoxiaCell LineCell SurvivalCobaltImidazolesIndolesMiceMuscle Fibers, SkeletalOxidative StressProtective AgentsReactive Oxygen SpeciesCobaltcobaltous chlorideImidazolesIndolesnecrostatin-1Protective AgentsReactive Oxygen Species

Identifiers

PMID29436688
PMCPMC5846651
OpenAlexW2789078779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.